Navigation Links
Improving RNA Amplification

Performance of New MessageAmp II on High Density Oligonucleotide Microarrays


New ArrayScript, an M-MLV RT engineered to maximize yields of full-length cDNA

Amplify as little as 100 ng of input RNA in a single round for GeneChip analysis

cRNA synthesis powered by MEGAscript, the best technology for in vitro transcription

High labeling efficiency yielding consistently high percent Present calls, and low 3'/5' ratios in GeneChip analysis


RNA amplification is often required for producing sufficient amounts of labeled target nucleic acid for detection by array hybridization. The original T7 RNA polymerase linear amplification method described and patented by Van Gelder and Eberwine [1-3] is the basis for sample preparation for most commercial microarray platforms, including the high quality Affymetrix GeneChip. At Ambion we recognize that there is more to improving RNA amplification than simply increasing yields of labeled cRNA. We therefore, set out to ensure that any observed improvements in amplification coincide with accepted standards for high quality expression profiling.


RNA Amplification Enhancements
Ambion is recognized as one of the key research companies for development of comprehensive solutions for cRNA (aRNA) amplification. Ambions MessageAmp aRNA Amplification Kit was the first commercially available Eberwine-based aRNA amplification kit. The MessageAmp II cRNA Amplification Kit incorporates extensive improvements to the original MessageAmp procedure. In developing MessageAmp II, Ambions scientists focused on the reverse transcription and second strand cDNA synthesis steps, both of which are critical for generating high yields of full-length labeled cRNA. This led to the development of ArrayScript, an engineered M-MLV reverse transcriptase, and to the optimization of the second strand cDNA synthesis reaction to synergize with the improvements gained with ArrayScript. One of the principal benefits conferred by ArrayScript and the optimized second-strand synthesis step is that MessageAmp II will generate sufficient labeled cRNA in a single round of amplification for array analysis from as little as 100 ng of total RNA (Figure 1). Other commercially available products for cRNA amplification usually demand two rounds of amplification at this level of input.

Figure 1. High Density Oligonucleotide Microarray Hybridized with MessageAmp II cRNA. Shown is a portion of a GeneChip array image used in this report. All RNA samples were amplified and labeled with biotin-16-UTP/-11-CTP (PerkinElmer Life Sciences), with the MessageAmp II Kit. Biotin labeled cRNA was fragmented, then hybridized and stained using GeneChip Human Genome Focus Arrays following the GeneChip Expression Analysis technical manual.


Together, the RT and second strand cDNA reactions result in an increase in the conversion of mRNA into longer double-stranded cDNA templates. This increase allows both shortened in vitro transcription (IVT) reaction incubation times and more reliable access to expression information from total RNA samples less than 1 g. The increase also translates through to two rounds of amplification, allowing more robust amplification of total RNA from 10 ng to as low as 100 pg.


Expectations for Yields
Factors such as tissue source, mRNA content (0.1-3%), starting amount of total RNA, and the quality of RNA used, will all affect the yield of cRNA. Collectively these factors can lead to up to 4-fold variation in yields. Figure 2 provides typical yields of cRNA amplified from six different sources using the MessageAmp II aRNA Amplification Kit. RNA inputs ranging from 50-3000 ng were tested from each source. From Figure 2 one can calculate the level of amplification obtained from different tissues at different inputs. The figure is also a useful benchmark for understanding the amount of cRNA produced both from different total RNA inputs and sources.

Figure 2. MessageAmp II aRNA Amplification Yields. Yields of cRNA (g) amplified using the MessageAmp II aRNA Amplification Kit from six different RNA sources using total RNA inputs of 50-3000 ng. Yields shown are the average of duplicate reactions. The in vitro transcription reaction incubation time was 4 hours for all samples. Purified cRNA concentrations were measured using a NanoDrop spectrophotometer.
*Universal Human Reference RNA (Stratagene)


One or Two Round Amplification?
Based on specific experimental constraints, researchers must decide whether one or two rounds of amplification are appropriate. Some microarray studies demand a high level of amplification (106 fold or greater), which can be achieved by two successive rounds of MessageAmp II reactions. Determining the lowest level of total RNA input that generates enough cRNA for array hybridization will depend on the amount of cRNA required for a particular microarray platform, and whether extra cRNA is desired for replicates, follow up validation with RT-PCR, or for archiving samples.

For consistency within an expression experiment, it is important to decide whether one or two rounds of amplification will be used throughout the study. For example, yields of total RNA may vary within a collection of samples some samples may yield 1 g of total RNA such that only one round of amplification is needed, whereas others may only yield 50 ng, requiring two rounds of amplification. Figure 3 may aid in this decision process for amplifying samples below 100 ng. For example, below 100 ng input RNA, the cRNA yields after one round of amplification may not be sufficient for most arrays.

Figure 3. cRNA Yields From Two Rounds of MessageAmp II Amplification. 100, 10, and 0.1 ng of total RNA from HeLa S3 cells (HeLa) and human inferior temporal cortex (brain) were amplified. Yields (g) using the MessageAmp II aRNA Amplification Kit are recorded for after each round of amplification. The starting cRNA input for the second round was 2 g (if available), or the entire amount obtained from the first round.


Obtaining sufficient cRNA for a microarray hybridization is not only dependent on the source of RNA being amplified but also on two reaction variables: the amount of input total RNA, and the length of the IVT incubation. The yield of cRNA increases with increasing RNA input and IVT time. As a rule, most samples between 100-1000 ng, incubated overnight (14 hr IVT), will produce sufficient cRNA for any microarray platform (at least 10 g). However when we investigated a range of IVT incubation times (from 4-14 hr), we found 4 hour IVT incubations generate sufficient cRNA from most total RNA inputs greater than 200 ng (Figure 4). A 4 hour IVT can be sufficient for 100 ng samples, and these conditions were used in the microarray studies presented below. (Note that mRNA poor samples will require longer IVT incubations (6-14 hr).

Figure 4. Plot of IVT Incubation Time vs. Yield. Total RNA (200 ng) from human inferior temporal cortex (brain) was amplified and incubated with in vitro transcription (IVT) reaction times of 4, 6, and 14 hours following the MessageAmp II protocol. The average yield of purified cRNA from duplicate amplification reactions was plotted versus the IVT incubation time. The 0,0 data point was added to extend the line to predict yields with IVT incubation times under 4 hours.


While we recommend a minimum of 4 hours for the IVT incubation, yields obtained from shorter time periods (2 or 3 hr) can be tested and should be adequate for input amounts above 500 ng.


Expression Analysis
Three approaches were used to define the reproducibility and consistency of the MessageAmp II protocol. First, the relative consistency of the MessageAmp II protocol was measured by comparing replicate arrays, where amplified samples originated from the same RNA source, either inferior temporal cortex from human brain (brain) or HeLa S3 cells (HeLa). These cRNA samples were hybridized to GeneChip Human Genome Focus Arrays following the Affymetrix guidelines. For a reference series we used the Affymetrix GeneChip 3'-Amplification Reagents One-Cycle cDNA Synthesis Kit and IVT Labeling Reagents (from here on referred to as the Affymetrix protocol) with duplicate 1000 ng reactions of the same RNA. The Affymetrix quality assessment guidelines were met for all arrays in this study. This included 3'/5' ratios (under 2.0), percent Present calls (50-53%), scaling factors, average background, as well as visual inspection of images. This assessment indicated that all arrays were of high quality.

MessageAmp II Reproducibility. Signal values for each probe set were converted from .CEL files into a summary of expression values measured for each of the 8793 probe sets (genes). Expression values were estimated using Robust Multi-array Average (RMA) [4-6] as implemented in BioConductor (www.bioconductor.org). The correlation established by this comparison shows that amplification using these protocols with 1000 ng of input total RNA is highly reproducible (Figure 5).

Figure 5. (A) Replicate Analysis of Two Amplification Protocols. Normalized signals are plotted from replicate amplifications. Both MessageAmp II (top) and Affymetrix standard protocol (bottom) were performed with the identical total RNA (1 g) and equivalent amounts were hybridized on matched lot Human Genome Focus arrays. All IVT reactions were performed for 4 hours. Correlation values are included and indicate a measure of reproducibility with both methods.(B) Correlation and Standard Deviation of Differences for RNA Inputs and IVT Incubation Times Compared to Standard. Two sources of total RNA brain and HeLa S3 cells, were used for amplification, and 4, 6, and 14 hr IVT reaction times were tested. For comparison the same information is provided for replicates of the Affymetrix protocol.


Differential Gene Expression. We also addressed differential gene expression between two different tissue sources (brain and HeLa). To measure the consistency of the MessageAmp II and the Affymetrix standard protocol, we plotted the possible replicates of the ratios for both protocols. Since there are two replicates of input RNA from brain and two from HeLa, for each protocol there are 4 possible ratios: 2 sets of 2 contain unique arrays.We compared the consistency of MessageAmp II and Affymetrix ratio estimates in Figure 6. There is generally good correspondence (higher correlation in the log2 ratios) of one replicate versus another in the MessageAmp II arrays relative to the Affymetrix arrays.

Figure 6. Scatter Plot of log2 Ratios of HeLa vs. Brain for MessageAmp II and Affymetrix Standard Protocol. Expression values were estimated using RMA. Log2 (HeLa/Brain) are plotted for each protocol represent the comparisons possible where the ratios are derived from unique arrays. HeLa and brain RNAs were amplified as stated in the MessageAmp II and Affymetrix protocols.


These two analyses (Figures 5 and 6) indicate that the two protocols are reproducible and comparisons made between the protocols do not appear to have any systematic differences above the observed variation between replicates within a protocol.

Present Absent Call Concordance. We used two comparisons to evaluate Present/Absent call concordance: 1) the correspondence of Present (P) and Absent (A) calls comparing the MessageAmp II and Affymetrix standard protocols to address consistency between protocols, and 2) the correspondence within the MessageAmp II and Affymetrix protocols. The P-A calls are based on the Wilcoxon signed rank-based gene expression Present/Absent detection algorithm first implemented in the Affymetrix Microarray Suite, Version 5. This was done separately by RNA type (brain and HeLa). We paired arrays in all possible combinations and summarized the average performance. When comparing two arrays, the percent shared Present (PSP) calls is the total genes called present in both arrays divided by the total number of (unique) genes called present between arrays. An equivalent statistic was used for the percent shared Absent (PSA) calls; for this analysis we ignored Marginal (M) calls. Also included was total concordance, calculated using all call types by simply dividing the number of concordant calls (P-P, A-A, or M-M) by the total number of calls (or genes = 8793). The results, shown in Figure 7, demonstrate again that the correspondence between the MessageAmp II and Affymetrix protocols was equivalent to that seen within Affymetrix replicates.

Figure 7. Comparison Between and Within Protocols of Mean Percent Shared Present and Absent Calls. Percent shared present (PSP) calls is the total genes called present in both arrays divided by the total number of (unique) genes called present between arrays. An equivalent statistic was used for the percent shared absent (PSA) calls; for this analysis we ignored marginal (M) calls. The right most column contains the total concordance, which is the number of concordant calls (P-P, A-A, or M-M) divided by the total number of calls (or genes = 8793). (Present/Absent calls were determined with Affymetrix GeneChip operating software (GCOS) for all arrays.)


IVT incubation time vs. Microarray Signals
While a shortened IVT time may produce sufficient cRNA for microarray hybridization, the signal characteristics of the labeled cRNA on a microarray is the critical factor for determining functionality. A series of three IVT time points (4, 6, and 14 hr) using total RNA from brain and HeLa were tested to measure whether any difference was observed between IVT times. Total RNA input amounts used were 100, 200 and 1000 ng. These samples were amplified and labeled as above, then hybridized to GeneChip Human Genome Focus Arrays. Again, for a reference series we used the Affymetrix protocol with duplicate 1000 ng reactions of the same RNA. Fourteen arrays were scanned and signal intensities were analyzed for similarity.

We first measured the simple correlation of the log2 expression of each array versus the chosen standard (1000 ng input; 4 hr IVT). Figure 5b lists the correlation and standard deviation (SD) of the differences with the standard. This data is also expressed as simple plots of log2 (expression) of each array versus the standard (x axis) (Figure 8). These comparisons reveal that the magnitude of the variation one sees among the different IVT times using 1000 ng RNA inputs and the MesageAmp II protocol is similar or less than expected in replicates using the Affymetrix protocol. Additionally, arrays with cRNA from 200 ng total RNA have more under-expressed genes (a broader tail on the left of each plot) for all times measured. This range of differences appears to be consistent with that also seen in Affymetrix replicates (Figure 5b). While the standard deviation (SD) of the differences between the 200 ng RNA inputs appears twice as large, combining replicates with simple averaging should decrease the SD.

Figure 8. Expression by IVT Time and RNA Input vs Standard. Log2 expression by IVT time and RNA Inputs (1000 ng and 200 ng) from IVT reactions incubated at 4, 6, or 14 hours were plotted versus the Standard (4 hr IVT; 1000 ng RNA input). The X and Y axis represent the log2 of the expression values estimated using RMA.


Expression Analysis at Lower RNA Inputs
Lower RNA inputs (below 100 ng), which generally require two rounds of amplification, suffer both a decrease in the percent Present calls and an increase in noise. Several studies have characterized and compared single vs. double round amplification [7, 8]. While possible, interpretation of expression profiles between samples that have been processed differently (single vs. double round amplification) is more problematic. Nevertheless, we attempted to measure the difference observed as the input levels are lowered to 10 ng of total RNA (approximately 1000 cell equivalents).

This experiment consisted of two variables: RNA input (1000, 100, and 10 ng), and amplification protocol (MessageAmp II vs. Affymetrix). For this analysis, both the 100 and 10 ng samples underwent two rounds of amplification.

Note that while the goal of the study was to compare array data generated after two rounds of amplification, MessageAmp II yields from one round of amplification with 100 ng inputs was actually sufficient for array hybridization. In this case, a single round of amplification would be preferred, as it would obviously improve correlation.

Again, we used 1000 ng input RNA as the standard to which we compared the other RNA input data (Figure 9A). Scatter plots of the log2 (expression) for both 100 and 10 ng RNA versus 1000 ng (within a protocol) is shown in Figure 9B. Obviously the 10 ng has much lower fidelity (correlation) with the standard for both MessageAmp II and Affymetrix.

Figure 9. (A) Correlation and Standard Deviation of Differences for RNA Input. Correlation and Standard Deviation are presented for differences in the brain samples, when comparing inputs of 10, 100, and 1000 ng to the standard (1000 ng). (B) Scatter Plots of Log2 (expression) by RNA amount. Each input is plotted vs the standard of 4 hour IVT using 1.0 g for both MessageAmp II (top row) and GeneChip IVT Labeling Kit (bottom row). The 0.1 g and 0.01 g samples are derived from two rounds of amplification.

As done previously, for comparison we used the standard deviation of the differences between two replicates of the standard (0.15 and 0.17). The results suggests that fidelity decreases with decreasing RNA input, but particularly for the 100 ng concentration, the correlation (and standard deviation of differences) is better for the MessageAmp II protocol than the Affymetrix standard protocol (0.3 vs. 0.55). At 10 ng inputs fidelity is lower. Nevertheless, the signal correlation indicates meaningful data can still be obtained (0.91 vs. 0.93). Again, in some cases two rounds of amplification are not needed (e.g. for 100 ng inputs with the MessageAmp II procedure), and in this case a comparison between the 1000 ng standard and 100 ng single round amplification is significantly more accurate and applicable.


Conclusion
The critical criteria for microarray sample preparation methods are: they must be highly reproducible, conserve the original mRNA profile, and be applicable with a reasonable range of total RNA inputs. While it is important that both amplification and labeling methods conserve the original expression profile, we realize that all methods will have some inherent bias [8]. Some of this bias can be minimized with a robust protocol and optimized reagents. The MessageAmp II aRNA Amplification Kit provides such a protocol and the novel reverse transcriptase (ArrayScript) for this purpose. We attempted to monitor correlation and standard deviation between two important factors, amplification protocol and RNA input. The data indicate that the MessageAmp II protocol is highly reproducible and can be meaningfully compared to the Affymetrix standard protocol and the original MessageAmp protocol (see sidebar, MessageAmp II Concordance with Original MessageAmp Kit). We hope to have provided some guidelines for amplification expectations and confidence that a shortened IVT incubation time that produces enough cRNA for a microarray will not significantly effect expression data (compared to longer IVT times). The above examples have been an important part of our research, production, and quality control development for procedures that we use to maintain the highest quality reagents for microarray analysis. We plan on continuing such studies for both new product development and improving our line of RNA amplification products.


Affymetrix and GeneChip are registered trademarks owned or used by Affymetrix, Inc.


back to top


Ordering Information
Cat# Product Name Size 1751 MessageAmp II aRNA Amplification Kit 20 rxns
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Improving the Efficiency of Common Filtration Tasks in your Laboratory
2. Improving an Integral Part of the Lab: Vacuum
3. Improving the accuracy and speed of mammalian cell counting
4. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
5. Simple Purification of DNA from Plasmid Minipreps, PCR Amplifications and Agarose Gels
6. Greater Amplification Specificity with New Hot Start PCR Enzyme
7. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
8. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
9. Improve Amplification Specificity with Hot Start PCR Enzyme
10. Amplification of the amoA Gene of Nitrosococcus oceani Bacteria Using Eppendorf MasterTaq
11. Amplification of Mouse cDNAs for Microarrays Using the Eppendorf MasterTaq Kit
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Improving RNA Amplification

(Date:5/30/2015)... , May 30, 2015 CTI BioPharma Corp. ... Bioscience business (NYSE: BAX ) today announced data ... examining pacritinib for the treatment of myelofibrosis – in ... Meeting of the American Society of Clinical Oncology (ASCO), ... Pacritinib is an investigational oral multikinase inhibitor ...
(Date:5/29/2015)... In recent years, the biopharmaceutical industry has ... that can generate valuable insights. Despite this, the inherent ... have caused the biopharmaceutical sector to embrace Big Data ... According to a recent study by benchmarking firm, Best ... Data team or function in place; however, these organizations ...
(Date:5/29/2015)... May 29, 2015 Asthma ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading asthma ... fumarate) and Xolair (omalizumab), the global market for asthma ... end of the decade.   New analysis ...
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4
... Novagali Pharma, a French,pharmaceutical ophthalmic company, announces ... (IND) to conduct a Phase III clinical,trial ... glaucoma has been,granted by the U.S. Food ... ocular proprietary BAK-free formulation of latanoprost which,furthermore ...
... Milestone Payment from GlaxoSmithKlineMOUNTAIN VIEW, Calif., May 5 ... identified an orally bioavailable small molecule antagonist of ... clinical development. The acceptance of the molecule ... milestone payment from the alliance with GlaxoSmithKline (NYSE: ...
... May 5 Amylin Pharmaceuticals, Inc., (Nasdaq: ... LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) ... once weekly has been submitted to the U.S. Food and ... release medication for type 2 diabetes that is injected subcutaneously ...
Cached Biology Technology:Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 3ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 2Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 3Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 5Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 6Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 7
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/10/2015)... May 11, 2015 Fingerprint Cards (FPC) ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... used by smartphone manufacturers in China . ... communicated revenue guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... 95 percent genomic similarity to humans, mice have long been ... Once researchers can shine a light on the genetic factors ... prevention and treatment options to protect the human population. ... difficult road, made more challenging by the 5% difference between ...
... shown that a dramatic sea-level rise occurred at the onset ... as the Blling warming, approximately 14,600 years ago. This event, ... rapid collapse of massive ice sheets 14,600 years ago and ... are published in the 29 March 2012 issue of the ...
... The Cardiovascular Cell Therapy Research Network (CCTRN), a ... Health,s (NIH) National Heart, Lung and Blood Institute (NHLBI) ... of its seven U.S. centers of excellence. The network ... over the next seven years to help achieve its ...
Cached Biology News:New lab mice cut search for genetic links to disease by more than a decade 2New lab mice cut search for genetic links to disease by more than a decade 3Ice sheet collapse and sea-level rise at the Boelling warming 14,600 years ago 2Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network 2